← Leaderboards
Eric James Rellinger
University Of Kentucky
$639,028
Attributed
$1,278,055
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $311.2K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,278,055 · 2
By mechanism
P20$1,278,055 · 2
Top collaborators
- Daret K St Clair4 shared
- Binhua P Zhou1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Bernard Mark Evers$41,615,341
- Mark B. Dignan$20,662,963
- Bernhard Hennig$8,918,317
- Philip A Kern$73,632,857
- Lisa A Cassis$35,386,044
Others in their field
Other Emerging Leaders on “Xenograft Procedure”
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,381,339
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Connie Suders · Leidos Biomedical Research, Inc.$19,812,417
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$6,727,999
- Yonathan Lissanu · University Of Tx Md Anderson Can Ctr$6,037,986
- Aaron Matthew Lebeau · University Of Wisconsin-Madison$5,853,982
Research focus
Xenograft ProcedureAngiogenesisSmall MoleculeSolid NeoplasmStable IsotopeSubcutaneousTumor GrowthTumor MetabolismUniversitiesUptakeXenograft Model3-DimensionalCancer Cell GrowthCancer CenterCell SurvivalCrispr/Cas TechnologyDropoutGlutamineHigh RiskIn VitroIn VivoKentuckyKnock-OutMalignant Neoplasms
Grant awards (5)
Targeting Glutamine Uptake via ASCT2 Inhibition in MYCN-amplified Neuroblastomas$243,398
P20 · FY2025 · GM · contact PI
Targeting Glutamine Uptake via ASCT2 Inhibition in MYCN-amplified Neuroblastomas$311,206
P20 · FY2024 · GM · contact PI
Targeting Glutamine Uptake via ASCT2 Inhibition in MYCN-amplified Neuroblastomas$311,214
P20 · FY2023 · GM · contact PI
Targeting Glutamine Uptake via ASCT2 Inhibition in MYCN-amplified Neuroblastomas$311,214
P20 · FY2022 · GM · contact PI
Targeting Glutamine Uptake via ASCT2 Inhibition in MYCN-amplified Neuroblastomas$101,023
P20 · FY2021 · GM · contact PI